Nls Pharmaceutics Ltd (NLSP)

Nov 18, 2024

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks

Nov 18, 2024

Nov 18, 2024

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire

Nov 18, 2024

Nov 15, 2024

NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks

Nov 15, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires Additional Shares in NLS Pharmac - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

Nov 14, 2024

Nov 14, 2024

NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com

Nov 14, 2024

Nov 14, 2024

500: Something went wrong - Investing.com India

Nov 14, 2024

Nov 12, 2024

Kadimastem Ltd. Faces Financial Uncertainty - TipRanks

Nov 12, 2024

Nov 06, 2024

NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks

Nov 06, 2024

Nov 05, 2024

What's Going On With NLS Pharmaceutics Shares Monday? - MSN

Nov 05, 2024

Nov 05, 2024

NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics and Kadimastem Announce Strategic Merger - TipRanks

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics, Kadimastem enter definitive merger agreement - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - MSN

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com Canada

Nov 05, 2024

Nov 04, 2024

Definitive Merger Agreement Reached Between NLS and Kadimastem - Sleep Review

Nov 04, 2024

Nov 04, 2024

NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India

Nov 04, 2024

Nov 04, 2024

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com

Nov 04, 2024

Nov 04, 2024

NLS Pharmaceutics Merges with Kadimastem for Strategic Growth - TipRanks

Nov 04, 2024

Nov 03, 2024

NLSP - Insider Financial

Nov 03, 2024

Oct 28, 2024

NLS Pharmaceutics Achieves Nasdaq Compliance Milestone - TipRanks

Oct 28, 2024

Oct 28, 2024

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire

Oct 28, 2024

Oct 28, 2024

NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com

Oct 28, 2024

Oct 22, 2024

NLS Pharmaceutics Strikes Debt Forgiveness Deal - TipRanks

Oct 22, 2024

Oct 21, 2024

NLS Pharmaceutics’ $3.2 Million Common Share Offering - Global Legal Chronicle

Oct 21, 2024

Oct 21, 2024

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire

Oct 21, 2024

Oct 19, 2024

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance

Oct 19, 2024

Oct 18, 2024

(NLSP) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 18, 2024

Oct 15, 2024

NLS Pharmaceutics Boosts Financial Standing with Key Moves - TipRanks

Oct 15, 2024

Oct 15, 2024

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - Yahoo Finance

Oct 15, 2024

Oct 11, 2024

NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks

Oct 11, 2024

Oct 11, 2024

NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks

Oct 11, 2024

Oct 08, 2024

NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com

Oct 08, 2024

Oct 08, 2024

NLS Pharmaceutics Shareholders Approve Agenda - TipRanks

Oct 08, 2024

Oct 04, 2024

NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com

Oct 04, 2024

Oct 01, 2024

NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks

Oct 01, 2024

Sep 27, 2024

NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com

Sep 27, 2024

Sep 25, 2024

NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com

Sep 25, 2024

Sep 25, 2024

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire

Sep 25, 2024

Sep 24, 2024

A year in review: NLS Pharmaceutics Ltd (NLSP)’s performance in the last year - US Post News

Sep 24, 2024

Sep 24, 2024

Market Highlights: NLS Pharmaceutics Ltd (NLSP) Ends on a Low Note at 0.14 - The Dwinnex

Sep 24, 2024

Sep 23, 2024

NLSP: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 23, 2024

Sep 19, 2024

NLS Pharmaceutics Shareholders Approve Key Measures - TipRanks

Sep 19, 2024

Sep 17, 2024

NLS Pharmaceutics Adjusts Warrants Terms - TipRanks

Sep 17, 2024

Sep 13, 2024

NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks

Sep 13, 2024

Sep 02, 2024

Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex

Sep 02, 2024

Aug 30, 2024

What was NLS Pharmaceutics Ltd (NLSP)’s performance in the last session? - US Post News

Aug 30, 2024

Aug 29, 2024

NLSP’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Aug 29, 2024

Aug 29, 2024

Market Update: NLS Pharmaceutics Ltd (NLSP) Sees Negative Movement, Closing at 0.16 - The Dwinnex

Aug 29, 2024

Aug 26, 2024

NLS Pharmaceutics Prepares for Share Consolidation - TipRanks

Aug 26, 2024